MedTrace Logo

Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

NCT02242071 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

Conditions

Interventions

BIOLOGICAL

Stem Cell

intrathecal autologous bone marrow mononuclear cell transplantation

Sponsors & Collaborators

  • Neurogen Brain and Spine Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2015-03-31
Completion
2016-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242071 on ClinicalTrials.gov